Adoptive transfer of TLR1/2 and 41BB agonist (3H3) treated pmel transgenic T cells into B16-F1 melanoma bearing mice resulted in improved tumor rejection and survival (11), highlighting that TLR signaling within CD8+ T cells can boost antitumor immunity. The gene discussed is CD8A; the disease is melanoma.